Hepatocellular Carcinoma
📧 Sign up to get email alerts when something new happens for Hepatocellular Carcinoma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-04-09EMA Authorised: Sorafenib Accord (sorafenib tosilate) — Accord Healthcare S.L.U.
The EMA authorised Sorafenib Accord (sorafenib tosylate) for hepatocellular carcinoma and renal cell carcinoma. Accord Healthcare S.L.U. is …
-
EMA approval · 2026-02-27EMA Authorised: Cabometyx (cabozantinib (s)-malate) — Ipsen Pharma
The EMA authorised Cabometyx (cabozantinib (s)-malate) for renal cell carcinoma and hepatocellular carcinoma in the EU, with Ipsen Pharma as…
-
EMA approval · 2026-02-11EMA Authorised: Imjudo (tremelimumab) — AstraZeneca AB
EMA has authorised Imjudo (tremelimumab) from AstraZeneca AB for hepatocellular carcinoma and non-small cell lung cancer.
-
EMA approval · 2025-03-28EMA Authorised: Nexavar (sorafenib) — Bayer AG
The EMA authorised Nexavar (sorafenib) for hepatocellular carcinoma and renal cell carcinoma. The decision date was 13 February 2025.
-
FDA approval · 2025-03-05FDA Approved: EOVIST — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved Bayer's supplemental application for EOVIST (gadoxetate disodium), updating its labeling related to use in MRI for detecting fo…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-01-27FDA Approved: CYRAMZA — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for CYRAMZA (ramucirumab) from Eli Lilly and Company.
-
FDA approval · 2024-11-26FDA Approved: SORAFENIB — Supplemental Application (Dr.Reddys Laboratories Inc)
FDA approved a supplemental application for sorafenib submitted by Dr. Reddy's Laboratories Inc. This action provides supplemental approval …
-
FDA approval · 2024-08-14FDA Approved: EOVIST — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for EOVIST (gadoxetate disodium) by Bayer, updating the product labeling. The change involves expans…
-
FDA approval · 2024-03-05FDA Approved: SORAFENIB TOSYLATE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA granted a supplemental approval for sorafenib tosylate (generic sorafenib) by Mylan Pharmaceuticals Inc., allowing the generic product t…
-
FDA approval · 2023-09-12FDA Approved: SORAFENIB — Supplemental Application (Yabao Pharmaceutical Co., Ltd. Beijing)
FDA approved a supplemental application for Sorafenib by Yabao Pharmaceutical Co., Ltd. Beijing under an ANDA.
-
FDA approval · 2023-09-12FDA Approved: SORAFENIB — Supplemental Application (Teva Pharmaceuticals, Inc.)
FDA approved a supplemental application for Sorafenib from Teva Pharmaceuticals, indicating regulatory action for the generic product. Soraf…
-
FDA approval · 2023-06-14FDA Approved: IMJUDO — Supplemental Application (AstraZeneca Pharmaceuticals LP)
The FDA approved a supplemental application for IMJUDO (tremelimumab) from AstraZeneca.
-
FDA approval · 2023-04-12FDA Approved: SORAFENIB — Original Application (Torrent Pharmaceuticals Limited)
The FDA approved Torrent Pharmaceuticals' original ANDA for sorafenib, a generic version of Nexavar, expanding access to the cancer therapy.
-
FDA approval · 2022-11-09FDA Approved: SORAFENIB — Original Application (Yabao Pharmaceutical Co., Ltd. Beijing)
FDA approved a generic sorafenib product from Yabao Pharmaceutical Co., Ltd. Beijing (ANDA 209050). The approval covers the same indications…
-
FDA approval · 2022-09-14FDA Approved: FLUOROURACIL — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for fluorouracil submitted by BluePoint Laboratories, indicating approval of an ANDA supplement. Thi…
-
FDA approval · 2022-06-07FDA Approved: SORAFENIB — Original Application (Dr.Reddys Laboratories Inc)
FDA approves the original application for a generic sorafenib product from Dr. Reddy's Laboratories Inc, expanding access to the cancer drug…
-
FDA approval · 2020-11-12FDA Approved: SORAFENIB — Original Application (Teva Pharmaceuticals, Inc.)
The FDA approved Teva's original application for a generic sorafenib product, enabling a generic version of the cancer drug Sorafenib to be …
-
FDA approval · 2020-09-10FDA Approved: SORAFENIB TOSYLATE — Original Application (Mylan Pharmaceuticals Inc.)
The FDA approved a generic sorafenib tosylate product from Mylan under an original application. Sorafenib is indicated for hepatocellular ca…
-
FDA approval · 2017-12-22FDA Approved: NEXAVAR — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
The FDA approved a supplemental application for Nexavar (sorafenib) submitted by Bayer HealthCare Pharmaceuticals Inc.
-
FDA approval · 2016-06-07FDA Approved: STIVARGA — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
The FDA approved a supplemental application for Stivarga (regorafenib) submitted by Bayer HealthCare Pharmaceuticals Inc.
-
FDA approval · 2014-11-10FDA Approved: STIVARGA — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for Stivarga (regorafenib) submitted by Bayer HealthCare Pharmaceuticals Inc. The action updates the…
-
FDA approval · 2013-10-16FDA Approved: EOVIST — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
The FDA has approved Bayer's supplemental application for Eovist (gadoxetate disodium), updating its labeling to expand its use as an MRI co…
-
FDA approval · 2013-09-13FDA Approved: STIVARGA — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for Stivarga (regorafenib) submitted by Bayer HealthCare Pharmaceuticals Inc.
-
FDA approval · 2012-08-24FDA Approved: NEXAVAR — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for Nexavar (sorafenib) submitted by Bayer HealthCare Pharmaceuticals Inc.
-
FDA approval · 2009-11-13FDA Approved: EOVIST — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for EOVIST (gadoxetate disodium) from Bayer HealthCare Pharmaceuticals Inc.